These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1111 related articles for article (PubMed ID: 33632231)

  • 21. Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy.
    Zhao P; Qiu L; Zhou S; Li L; Qian Z; Zhang H
    Int J Nanomedicine; 2021; 16():2107-2121. PubMed ID: 33737808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor microenvironment-responsive macrophage-mediated immunotherapeutic drug delivery.
    Zhang X; Yue L; Cao L; Liu K; Yang S; Liang S; Liu L; Zhao C; Wu D; Wang Z; Tian R; Rao L
    Acta Biomater; 2024 Sep; 186():369-382. PubMed ID: 39097127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases.
    Mu X; Zhang M; Wei A; Yin F; Wang Y; Hu K; Jiang J
    Nanoscale; 2021 May; 13(19):8998-9008. PubMed ID: 33973580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted delivery of anti-miRNA21 sensitizes PD-L1
    Kim EH; Choi J; Jang H; Kim Y; Lee JW; Ryu Y; Choi J; Choi Y; Chi SG; Kwon IC; Yang Y; Kim SH
    Theranostics; 2024; 14(10):3777-3792. PubMed ID: 38994018
    [No Abstract]   [Full Text] [Related]  

  • 25. Bio-orthogonal click chemistry strategy for PD-L1-targeted imaging and pyroptosis-mediated chemo-immunotherapy of triple-negative breast cancer.
    Wang Y; Chen Y; Ji DK; Huang Y; Huang W; Dong X; Yao D; Wang D
    J Nanobiotechnology; 2024 Aug; 22(1):461. PubMed ID: 39090622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
    Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
    Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice.
    Bastaki S; Aravindhan S; Ahmadpour Saheb N; Afsari Kashani M; Evgenievich Dorofeev A; Karoon Kiani F; Jahandideh H; Beigi Dargani F; Aksoun M; Nikkhoo A; Masjedi A; Mahmoodpoor A; Ahmadi M; Dolati S; Namvar Aghdash S; Jadidi-Niaragh F
    Life Sci; 2021 Feb; 266():118847. PubMed ID: 33309720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
    Zhang R; Wan Y; Lv H; Li F; Lee CS
    J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor microenvironment-activated cancer cell membrane-liposome hybrid nanoparticle-mediated synergistic metabolic therapy and chemotherapy for non-small cell lung cancer.
    Zhang W; Gong C; Chen Z; Li M; Li Y; Gao J
    J Nanobiotechnology; 2021 Oct; 19(1):339. PubMed ID: 34689761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequentially responsive biomimetic nanoparticles with optimal size in combination with checkpoint blockade for cascade synergetic treatment of breast cancer and lung metastasis.
    Yu W; He X; Yang Z; Yang X; Xiao W; Liu R; Xie R; Qin L; Gao H
    Biomaterials; 2019 Oct; 217():119309. PubMed ID: 31271855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multifunctional Nanoparticles Boost Cancer Immunotherapy Based on Modulating the Immunosuppressive Tumor Microenvironment.
    Li J; Zhao M; Sun M; Wu S; Zhang H; Dai Y; Wang D
    ACS Appl Mater Interfaces; 2020 Nov; 12(45):50734-50747. PubMed ID: 33124808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrated Nanorod-Mediated PD-L1 Downregulation in Combination with Oxidative-Stress Immunogene Therapy against Cancer.
    Wu S; Zhang J; Pan J; Bai S; Wang Z; Chen Y; Xu D; An Y; Liu C; Chu C; Dai Q; Jiang L; Lu Z; Liu G
    Adv Healthc Mater; 2023 Jul; 12(17):e2300110. PubMed ID: 36773310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Three-in-one": A Photoactivable Nanoplatform Evokes Anti-Immune Response by Inhibiting BRD4-cMYC-PDL1 Axis to Intensify Photo-Immunotherapy.
    Mohanty A; Lee M; Mohapatra A; Lee H; Vasukutty A; Baek S; Lee JY; Park IK
    Adv Healthc Mater; 2024 Jul; 13(17):e2304093. PubMed ID: 38409920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multifunctional Redox-Responsive Nanoplatform with Dual Activation of Macrophages and T Cells for Antitumor Immunotherapy.
    Zhang W; Liu X; Cao S; Zhang Q; Chen X; Luo W; Tan J; Xu X; Tian J; Saw PE; Luo B
    ACS Nano; 2023 Aug; 17(15):14424-14441. PubMed ID: 37498878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Tumor Environment-Activated Photosensitized Biomimetic Nanoplatform for Precise Photodynamic Immunotherapy of Colon Cancer.
    Xiong M; Zhang Y; Zhang H; Shao Q; Hu Q; Ma J; Wan Y; Guo L; Wan X; Sun H; Yuan Z; Wan H
    Adv Sci (Weinh); 2024 Jul; 11(28):e2402465. PubMed ID: 38728587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1.
    Roux C; Jafari SM; Shinde R; Duncan G; Cescon DW; Silvester J; Chu MF; Hodgson K; Berger T; Wakeham A; Palomero L; Garcia-Valero M; Pujana MA; Mak TW; McGaha TL; Cappello P; Gorrini C
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4326-4335. PubMed ID: 30770442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene augmented nuclear-targeting sonodynamic therapy via Nrf2 pathway-based redox balance adjustment boosts peptide-based anti-PD-L1 therapy on colorectal cancer.
    Wan G; Chen X; Wang H; Hou S; Wang Q; Cheng Y; Chen Q; Lv Y; Chen H; Zhang Q
    J Nanobiotechnology; 2021 Oct; 19(1):347. PubMed ID: 34715867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
    Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
    Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer.
    Zhu W; Bai Y; Zhang N; Yan J; Chen J; He Z; Sun Q; Pu Y; He B; Ye X
    J Mater Chem B; 2021 May; 9(20):4201-4210. PubMed ID: 33997867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Trojan Horse Delivery Vehicle Carrying siRNA Nanotherapeutics with Multiple Tumor Microenvironment Responsiveness Elicits Robust Antitumor Immune Responses In Situ via a "Self-Synergistic" Approach.
    Fang Y; Chen S; Zhang M; Lin X; Jin X; Zhang M; Liu Y; Wang Y; Shi K
    Adv Healthc Mater; 2023 Nov; 12(28):e2301401. PubMed ID: 37537715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.